Deep Track Capital Reduces Stake in Definium Therapeutics (MNMD) to 3.01%

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, filed a Schedule 13G/A on May 15, 2026, disclosing a significant reduction in their position in Definium Therapeutics, Inc. (ticker: MNMD). As of the event date on March 31, 2026, the reporting persons beneficially own 3,000,000 shares of common stock, representing 3.01% of the company. This is a decrease from their previous holding of 5,676,540 shares, which accounted for a 5.54% ownership stake. The filing indicates that the shares are held with shared voting and dispositive power. Because the ownership level has fallen below the 5% threshold, the reporting persons have indicated that they no longer hold a reportable stake under certain beneficial ownership requirements, as noted in Item 5 of the filing. The investment is characterized as passive, with the reporting persons certifying that the shares were not acquired for the purpose of influencing or changing the control of the issuer. The calculation is based on 99,698,129 shares outstanding.